Since ferroptosis might contribute to the progression of NAFLD, we adopted a specific inhibitor of ferroptosis, deferoxamine (DFO), to explore the correlation between TRIM59 and ferroptosis. Here, TRIM59 is linked to metabolic dysfunction-associated steatotic liver disease.